Completed PHASE2 INTERVENTIONAL NCT00211445

Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)

Sponsor: Manhattan Eye, Ear & Throat Hospital

Conditions Chronic Central Serous Chorioretinopathy

Interventions Photodynamic Therapy with Verteporfin verteporfin

Updated 5 times since 2017 Last updated: Sep 27, 2007 Started: Jul 31, 2002 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00211445, this PHASE2 trial focuses on Chronic Central Serous Chorioretinopathy and remains completed. Sponsored by Manhattan Eye, Ear & Throat Hospital, it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Manhattan Eye, Ear & Throat Hospital

Data source: Manhattan Eye, Ear & Throat Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States